{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:39:22Z","timestamp":1782823162856,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.vaccine.2021.09.052","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T07:08:36Z","timestamp":1632467316000},"page":"6520-6528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"title":["A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18\u201359\u00a0years: An interim analysis in Indonesia"],"prefix":"10.1016","volume":"39","author":[{"given":"Eddy","family":"Fadlyana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kusnandi","family":"Rusmil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodman","family":"Tarigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andri Reza","family":"Rahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susantina","family":"Prodjosoewojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1409-6010","authenticated-orcid":false,"given":"Yulia","family":"Sofiatin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Citra V.","family":"Khrisna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rini Mulia","family":"Sari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilis","family":"Setyaningsih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fikrianti","family":"Surachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novilia Sjafri","family":"Bachtiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6849-5175","authenticated-orcid":false,"given":"Hadyana","family":"Sukandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imam","family":"Megantara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysanti","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisna Nur A.","family":"Pangesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivi","family":"Setiawaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunarjati","family":"Sudigdoadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cissy B.","family":"Kartasasmita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.09.052_b0005","first-page":"388","article-title":"COVID-19 Vaccines: Current Status and Implication for Use in Indonesia","volume":"52","author":"Ophinni","year":"2020","journal-title":"Acta Med Indones"},{"key":"10.1016\/j.vaccine.2021.09.052_b0010","article-title":"Coronavirus disease (COVID-19)","author":"WHO","year":"2020","journal-title":"Situation Report-132."},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.052_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0972063420921260","article-title":"Coronavirus Pandemic: A Serious Threat to Humanity","volume":"22","author":"Gupta","year":"2020","journal-title":"J Health Manag"},{"issue":"8","key":"10.1016\/j.vaccine.2021.09.052_b0020","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.052_b0025","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S2213-2600(20)30162-4","article-title":"Monitoring the COVID-19 epidemic in the context of widespread local transmission","volume":"8","author":"Garc\u00eda-Basteiro","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2021.09.052_b0030","unstructured":"WHO Director-General\u2019s opening remarks at the media briefing on COVID-19 - 11 March 2020 n.d. https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (accessed January 23, 2021)."},{"key":"10.1016\/j.vaccine.2021.09.052_b0035","first-page":"4","article-title":"Weekly Epidemiological Update on COVID-19","volume":"1","author":"World Health Organization","year":"2020","journal-title":"World Heal Organ"},{"key":"10.1016\/j.vaccine.2021.09.052_b0040","unstructured":"WHO. Situation Report-7 INDONESIA Situation Report 19 Internal for SEARO. 2020."},{"key":"10.1016\/j.vaccine.2021.09.052_b0045","unstructured":"Wenjiang Fu1 2*, Jieni Li3 and Paul Scheet 4. Covid-19 Vaccine Efficacy: Accuracy, Uncertainty and Projection of Cases. MedRxiv 2020. 10.1101\/2020.12.16.20248359."},{"issue":"21","key":"10.1016\/j.vaccine.2021.09.052_b0050","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 Vaccines at Pandemic Speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.09.052_b0055","unstructured":"WHO. WHO R&D Blueprint novel Coronavirus Outline of designs for experimental vaccines and therapeutics. vol. 205. 2020."},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.052_b0060","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.vaccine.2021.09.052_b0065","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.vaccine.2009.01.125","article-title":"Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring","volume":"27","author":"Vellozzi","year":"2009","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2021.09.052_b0070","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0264-410X(95)00211-I","article-title":"Inactivated poliovirus vaccine: Past and present experience","volume":"14","author":"Murdin","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.09.052_b0075","unstructured":"(WHO) WHO. Draft landscape and tracker of COVID-19 candidate vaccines 2021. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines (accessed January 25, 2021)."},{"issue":"6499","key":"10.1016\/j.vaccine.2021.09.052_b0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science (80-)"},{"key":"10.1016\/j.vaccine.2021.09.052_b0085","article-title":"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years","author":"Zhang","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.09.052_b0090","unstructured":"KEMENKES. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07\/MenKes\/413\/2020 Tentang Pedoman Pencegahan dan Pengendalian Corona Virus Disease 2019 (Covid-19). MenKes\/413\/2020 2020;2019:207."},{"issue":"7","key":"10.1016\/j.vaccine.2021.09.052_b0095","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.052_b0100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","article-title":"Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses","volume":"41","author":"Jiang","year":"2020","journal-title":"Trends Immunol"},{"key":"10.1016\/j.vaccine.2021.09.052_b0105","first-page":"25","article-title":"SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors","volume":"17","author":"Grzelak","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.vaccine.2021.09.052_b0110","unstructured":"SAGE (Strategic Advisory Group of Experts). Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19. 2021."},{"key":"10.1016\/j.vaccine.2021.09.052_b0115","unstructured":"Tanriover MD, Do\u011fanay HL, Akova M, G\u00fcner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021;398:213\u201322. 10.1016\/S0140-6736(21)01429-X."},{"issue":"10","key":"10.1016\/j.vaccine.2021.09.052_b0120","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.09.052_b0125","unstructured":"Sinovac Announces Phase III Results of Its COVID-19 Vaccine-SINOVAC - Supply Vaccines to Eliminate Human Diseases n.d. http:\/\/www.sinovac.com\/?optionid=754&auto_id=922 (accessed March 17, 2021)."},{"key":"10.1016\/j.vaccine.2021.09.052_b0130","unstructured":"CDC. Principles of Epidemiology | Lesson 3 - Section 6 n.d. https:\/\/www.cdc.gov\/csels\/dsepd\/ss1978\/lesson3\/section6.html (accessed February 22, 2021)."},{"key":"10.1016\/j.vaccine.2021.09.052_b0135","unstructured":"Fda, Cber. Contains Nonbinding Recommendations Development and Licensure of Vaccines to Prevent COVID-19 Guidance for Industry. 2020."},{"key":"10.1016\/j.vaccine.2021.09.052_b0140","unstructured":"Fda, Cber. Contains Nonbinding Recommendations Emergency Use Authorization for Vaccines to Prevent COVID-19 Guidance for Industry Preface Public Comment. 2020."},{"key":"10.1016\/j.vaccine.2021.09.052_b0145","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.vaccine.2021.09.052_b0150","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine _ Enhanced Reader.pdf","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.09.052_b0155","unstructured":"(WHO) WHO. CONSIDERATIONS FOR EVALUATION OF COVID19 VACCINES 2020;21:1\u201314. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines (accessed January 25, 2021)."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2101255X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2101255X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:03:12Z","timestamp":1759402992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2101255X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":31,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0264410X2101255X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.052","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18\u201359\u00a0years: An interim analysis in Indonesia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}